Blood perfusion device to reduce secondary infection in hospital

Abstract

The present disclosure relates to a blood perfusion device, and more specifically to a blood perfusion device which includes an anti-mtFP antibody to remove mtFP, thereby blocking the binding of mtFP to formyl peptide receptor 1 (FPR1) on the PMN membrane by removing the mtFP, and is capable of suppressing the occurrence of secondary infection in hospital by restoring the chemotaxis of polymorphonuclear leukocytes (PMN). The present disclosure can reduce late death and improve long-term survival by improving the clinical course of sepsis patients recovering after the acute phase, and it is expected to improve long-term survival by suppressing the occurrence of secondary infections in hospital for patients who require long-term hospitalization in the intensive care unit or hospital room, such as severe trauma patients, organ transplant patients and patients surviving after cardiac arrest.

Dependencies are inferred from the claim text.